Shares of ImmunityBio Inc. (IBRX) are jumping Friday morning. The reason? The company just crossed a major manufacturing finish line for its natural killer cell therapy platform. Think of it like a biotech company finally figuring out how to mass-produce a complex, living drug—and proving it's safe to use.

So, what did they actually do?

ImmunityBio wrapped up two key programs, NK2022 and NK2023, which were all about testing the safety and reproducibility of its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy. In plain English, they took immune cells from patients, supercharged them in the lab to fight cancer, and then put them back. The big news: across 64 subjects, they reported zero serious adverse events.

But the real headline is the scale. The company says it can now generate up to five billion of these NK cells from just one apheresis collection—that's a process of drawing and separating a patient's blood. That single batch can yield eight to ten therapeutic doses, all within a 12-day turnaround. For a field where manufacturing complexity often limits treatment availability, that's a big deal.

The company isn't stopping there. It's already advancing a phase 1 trial (QUILT-3.076) that combines these M-ceNK cells with its drug ANKTIVA, which has shown promising antitumor activity across multiple cancer types.

The "World Bank of Natural Killer Cells"

Patrick Soon-Shiong, ImmunityBio's founder and executive chairman, framed the achievement ambitiously. "These data demonstrate that potent NK cell therapy can be manufactured at scale and administered safely, potentially offering a reliable autologous source of potent NK cells," he said.

He added, "The ability to generate up to five billion highly pure NK cells from a single apheresis collection, yielding up to eight to 10 therapeutic doses within 12 days, opens the possibility of creating the 'World Bank of Natural Killer Cells,' with NK cells able to be universally donated to any patient without HLA matching." In other words, this scalable process could one day make these powerful cells an off-the-shelf resource, bypassing complex donor matching.

Regulatory Momentum on Another Front

Separately, the company is making progress with regulators. On Monday, the FDA acknowledged receipt of ImmunityBio's resubmitted application for ANKTIVA to treat a type of bladder cancer. This follows ongoing discussions that began earlier this year, after the agency requested more data. The company submitted updated efficacy information in March.

What the Street Thinks

The analyst consensus on ImmunityBio remains positive, with a Buy rating and an average price target of $12.57. Recent moves include:

• BTIG: Initiated with a Buy rating and a $13 target on March 12.
• D. Boral Capital: Maintained a Buy rating with a $23 target on March 9.
• Piper Sandler: Maintained an Overweight rating and raised its price target to $12 on March 4.

For ETF investors, the stock has notable exposure in the Virtus LifeSci Biotech Products ETF (BBP), where it carries a 4.03% weight.

At the time of reporting, ImmunityBio shares were up 10.60% at $8.65.